Stockreport

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)  (TAK) 
PDF - Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial- FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in the EU for Metastatic Colorecta [Read more]